Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02434354
Title A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.